LASP1 Antibody (Center) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q14847 |
---|---|
Clone Names | 100528126 |
Gene ID | 3927 |
---|---|
Other Names | LIM and SH3 domain protein 1, LASP-1, Metastatic lymph node gene 50 protein, MLN 50, LASP1, MLN50 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | LASP1 |
---|---|
Synonyms | MLN50 |
Function | Plays an important role in the regulation of dynamic actin- based, cytoskeletal activities. Agonist-dependent changes in LASP1 phosphorylation may also serve to regulate actin-associated ion transport activities, not only in the parietal cell but also in certain other F-actin-rich secretory epithelial cell types (By similarity). |
Cellular Location | Cytoplasm, cell cortex. Cytoplasm, cytoskeleton. Note=Associated with the F-actin rich cortical cytoskeleton. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes a member of a LIM protein subfamilycharacterized by a LIM motif and a domain of Src homology region 3.The encoded protein functions as an actin-binding protein andpossibly in cytoskeletal organization.
References
Traenka, C., et al. Cancer Res. 70(20):8003-8014(2010)Zhao, L., et al. FEBS J. 277(20):4195-4204(2010)Zhao, L., et al. Gut 59(9):1226-1235(2010)Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) :Frietsch, J.J., et al. Br. J. Cancer 102(11):1645-1653(2010)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.